Evaluating serum lactate levels in patients with ulcerative colitis
Serum Lactate and Mean Platelet Volume as Predicators for Acute Exacerbation in Patients With Ulcerative Colitis
This study is testing if measuring lactate levels in the blood can help doctors better understand how severe ulcerative colitis symptoms are in patients who need to be hospitalized.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 137 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Assiut) |
| Trial ID | NCT05876494 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with severe symptoms of ulcerative colitis (UC) who require hospitalization for urgent assessment and therapy. It aims to explore the relationship between serum lactate levels and disease activity in UC, as current biomarkers like ESR and CRP have low specificity and sensitivity. The study will assess the potential of serum lactate as a more reliable indicator of disease severity compared to traditional methods, while also considering the risks associated with full colonoscopy in acute settings.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with ulcerative colitis.
Not a fit: Patients with inflammatory bowel diseases other than ulcerative colitis, such as Crohn's disease, or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more accurate and safer method for assessing disease activity in ulcerative colitis patients.
How similar studies have performed: While there is ongoing research into various biomarkers for ulcerative colitis, the specific focus on serum lactate as a potential indicator of disease activity is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: Any patient who is above age of 18 years old and diagnosed to have UC based on combination between clinical, laboratory, radiological, endoscopic and/or histopathological data whatever the course of the disease Exclusion criteria * Patients with inflammatory bowel disease (IBD) other than UC as those with Crohn's disease or microscopic colitis * Pregnant patients with ulcerative colitis. * Patients with UC who are under age of 18 years old * Patient's refusal
Where this trial is running
Assiut
- Ahmed Mohammed Abu-Elfatth — Assiut, Egypt (Recruiting)
Study contacts
- Principal investigator: Ahmed M Abu-Elfatth — Assiut University
- Study coordinator: Ahmed M Abu-Elfatth
- Email: ahmed111@aun.edu.eg
- Phone: +18677791
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.